Am J Clin Pathol 2019 09;152(4):479-485
Department of Pathology, University of Utah, Salt Lake City.
Objectives: To review impact of the ASCO/CAP 2018 update on HER2 testing.
Methods: HER2 fluorescence in situ hybridization (FISH) test requests from primary and metastatic breast cancers between August 2018 and January 2019 were included. FISH results requiring a changed algorithm under the new guidelines (groups 2, 3, and 4) were identified and HER2:CEN17 ratios, average HER2, CEN17 signals/cell, and HER2 immunohistochemistry (IHC) results were recorded. Read More